HNSCC
88
36
45
20
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
4.5%
4 terminated out of 88 trials
83.3%
-3.2% vs benchmark
6%
5 trials in Phase 3/4
35%
7 of 20 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 20 completed trials
Clinical Trials (88)
Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors
Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Nano-Carbon Iron Suspension Injection Combined With Radiotherapy for Solid Tumors Phase II Clinical Trial
Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC
DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors
Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer